Merrill Lynch Stick to Their Buy Rating for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, and that is roughly 9.11 % above the present share price of $76.07.

Cherny expects CVS Health Corp to publish earnings per share (EPS) of $0.93 for the earliest quarter of 2021.

The present opinion among eleven TipRanks analysts is actually for a moderate Buy rating of shares in CVS Health, with an average price aim of $84.

The analysts price targets range from a high of $101 to a low of sixty one dolars.

From the latest earnings report of its, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net gain of $3.25 billion. The company’s market cap is actually $99.57 billion.

According to TipRanks.com, Merrill Lynch analyst Michael Cherny is now ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 11.5 % and a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It works through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The Long or retail Term Care segment has offering of prescription medications as well as assortment of general merchandise.

The Health Care Benefits segment offers quite traditional, voluntary and consumer-directed health insurance products as well as related services, including medical, pharmacy, dental, behavioural health, medical control abilities. The Corporate segment involves in offering management and administrative services. The company was founded by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.

Leave a comment

Your email address will not be published. Required fields are marked *